Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. The amino acid sequence of the GLP1R peptide agonist (eGLP1) (19) used for conjugation.
  • Fig. S2. Scheme 1, synthesis of eGLP1-conjugated MALAT1 (9), FOXO1 (10), and scrambled control (11) ASOs.
  • Fig. S3. The sequences of MALAT1, FOXO1, and scrambled control cEt gapmer ASOs used for conjugation to the eGLP1 peptide, sequence, and structural information.
  • Fig. S4. Effects of MALAT1-ASO and eGLP1-MALAT1-ASO treatment on gene expression in vitro in non–GLP1R-expressing cell lines.
  • Fig. S5. ASO uptake, MALAT1, and FOXO1 gene expression in liver from mice.
  • Fig. S6. Receptor gene expression in islets and liver from mice treated with MALAT1-ASO and eGLP1-MALAT1-ASO.
  • Fig. S7. FOXO1 mRNA levels in islets and liver from mice treated over 6 weeks with FOXO1-ASO and eGLP1-FOXO1-ASO in vivo.
  • Table S1. In vitro pharmacology potencies on GLP1R signaling pathways.
  • Table S2. In vitro pharmacology potencies reducing target gene expression in cell lines.
  • Table S3. In vivo parameter estimates of treatment effects on gene expression in isolated islets from mice 72 hours after single subcutaneous dose of eGLP1-MALAT1-ASO and eGLP1-FOXO1-ASO.

Download PDF

Files in this Data Supplement: